A Retrospective Analysis Comparing Orca-T to Post-Transplant Cyclophosphamide Based Allogeneic Hematopoietic Cell Transplant in Patients with Matched Unrelated Donors Receiving Myeloablative Conditioning

Identifying an allogeneic hematopoietic cell transplantation (HCT) modality that can reduce graft versus host disease (GvHD), lower non-relapse mortality (NRM), and increase relapse free survival (RFS) is the key to improving outcomes for patients with hematologic malignancies.Recently, the utilization of post-transplant cyclophosphamide (PTCy) as a prophylaxis against GvHD has increased; however, PTCy-based HCTs after myeloablative conditioning are associated with higher toxicities requiring prolonged hospitalization, NRM and relapse at 1-year.

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Alexandra Gomez-Arteaga, Caspian Oliai, Sagar S. Patel, Jeremy Pantin, Arpita P Gandhi, Amandeep Salhotra, Dr. Bhagirathbhai Dholaria, Edmund K. Waller, Samer A. Srour, Anna Pavlova, Irene Agodoa, James Scott McClellan, Nathaniel B. Fernhoff, Mehrdad Abed Tags: 59 Source Type: research